RBMS1 and breast cancer: The effect of YC-1 could therefore be 2-fold; inhibition of HIF-1α and downregulation of PR, making it a uniquely suitable small molecule drug for combating those forms of breast cancer which are largely dependent on the actions of progestins to stimulate the production of VEGF.